![]() | |
Type | Public |
---|---|
LSE: DPH | |
Industry | Pharmaceuticals |
Founded | 1997 |
Headquarters | , |
Key people | Tony Rice, (Chairman) Ian Page, (CEO) |
Revenue | ![]() |
![]() | |
![]() | |
Website | www.dechra.com |
Dechra Pharmaceuticals PLC is an England-based business involved in the development and marketing of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62 million.[3] In 2010 it purchased Florida-based DermaPet for US$64 million[4] and Sussex-based Genitrix for £5 million.[5]
It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[6]
Operations
The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[7]
See also
References
- ^ a b c "Annual Report 2020". Dechra Pharmaceuticals. Retrieved 28 February 2021.
- ^ a b Montague Private Equity announces sale of VetXX
- ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
- ^ "Dechra Pharma buys DermaPet for US$64 mln". Proactive Investors. 22 October 2010. Retrieved 1 March 2020.
- ^ "Dechra acquires Sussex-based Genitrix in a £5.4m deal". Business Live. 1 December 2010. Retrieved 1 March 2020.
- ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
- ^ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.